Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | ADA | P00813 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28290150 | 0.78 | LTA4H (0.40) | LTA4HHDAC6CYP19A1MEN1HPGD | |
| SCHEMBL3670589 | 0.78 | CYP1A2 (0.40) | LTA4HHDAC6MEN1HPGDKMT2A | |
| SCHEMBL754082 | 0.69 | ADORA2A (0.47) | LTA4HHDAC6MEN1KMT2AHDAC1 | |
| SCHEMBL27682122 | 0.66 | ADORA2A (0.38) | LTA4HHDAC6HDAC1 | |
| SCHEMBL25936242 | 0.66 | ADORA2A (0.38) | LTA4HHDAC6HDAC1 | |
| SCHEMBL6664459 | 0.66 | HDAC6 (0.58) | LTA4HHDAC6 | |
| SCHEMBL325140 | 0.66 | HDAC1 (0.61) | LTA4HHDAC6MEN1KMT2AHDAC1 | |
| SCHEMBL10574342 | 0.64 | KMT2A (0.50) | LTA4HMEN1KMT2A | |
| SCHEMBL3671304 | 0.63 | LTA4H (0.50) | LTA4HHDAC6HDAC1 | |
| SCHEMBL8593200 | 0.63 | LTA4H (0.47) | LTA4HHDAC6MEN1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825136-B2 | Potentiators of antibacterial activity | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-02 | — | — | US | disclosed |
| US-20090291964-A1 | Potentiators of Antibacterial Activity | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-26 | — | — | US | disclosed |
| US-20050090482-A1 | mixture of antibiotics, carriers and activators such as (S)-1-((3,4,5-Trimethoxyphenyl)-methyl-carbamoyl)-piperidine-2-carboxylic acid 4-pyridin-3-yl-1-(3-pyridin-3-yl-propyl)-butyl ester, used for treatment of bacterial infection in mammals | VERTEX PHARMACEUTICALS INCORPORATED | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291964-A1 | Potentiators of Antibacterial Activity | SLC11A2, MPO, ABCB11 | LTA4H 1214/4885HDAC6 1681/4885CYP19A1 3113/4885 |
| US-20050090482-A1 | mixture of antibiotics, carriers and activators such as (S)-1-((3,4,5-Trimethoxyphenyl)-methyl-carbamoyl)-piperidine-2-carboxylic acid 4-pyridin-3-yl-1-(3-pyridin-3-yl-propyl)-butyl ester, used for treatment of bacterial infection in mammals | TLR1, ABCB11, SLC7A1 | LTA4H 1084/4885HDAC6 702/4885CYP19A1 3756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.